2023 - Research.com Medicine in United States Leader Award
2022 - Research.com Best Scientist Award
2012 - Warren Alpert Foundation Prize For the discovery, preclinical and clinical development of bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma.
Paul G. Richardson spends much of his time researching Multiple myeloma, Internal medicine, Bortezomib, Cancer research and Surgery. His work carried out in the field of Multiple myeloma brings together such families of science as Pharmacology and Dexamethasone. His Internal medicine research incorporates elements of Gastroenterology and Oncology.
The Bortezomib study which covers Proteasome inhibitor that intersects with Angiogenesis. The study incorporates disciplines such as Cell culture, Apoptosis, Protein kinase B, Cell growth and Bone marrow in addition to Cancer research. His studies in Surgery integrate themes in fields like Ixazomib and Hazard ratio.
His primary scientific interests are in Internal medicine, Multiple myeloma, Bortezomib, Oncology and Lenalidomide. His Internal medicine research includes elements of Gastroenterology and Surgery. His Multiple myeloma research incorporates themes from Cancer research and Dexamethasone.
His Bortezomib course of study focuses on Pharmacology and In vivo. His Oncology research is multidisciplinary, incorporating elements of Relapsed refractory, Clinical trial, Refractory Multiple Myeloma and Daratumumab. His Lenalidomide study combines topics in areas such as Regimen, Tolerability and Maintenance therapy.
The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide. His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Defibrotide. His study focuses on the intersection of Multiple myeloma and fields such as Cancer research with connections in the field of Immune system.
His Dexamethasone research is multidisciplinary, incorporating perspectives in Clinical endpoint, Refractory and Subgroup analysis. He has researched Lenalidomide in several fields, including Maintenance therapy, Progression-free survival, Neutropenia and Hazard ratio. His biological study spans a wide range of topics, including Proteasome inhibitor, Proteasome and Phases of clinical research.
Paul G. Richardson mainly investigates Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide. His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology. As part of his studies on Multiple myeloma, Paul G. Richardson frequently links adjacent subjects like Progression-free survival.
His research integrates issues of Clinical trial, Refractory, Stem cell, Disease and Monoclonal antibody in his study of Oncology. His Dexamethasone research includes themes of Relapsed refractory, Clinical endpoint and Cancer research. His study looks at the relationship between Bortezomib and fields such as Proteasome inhibitor, as well as how they intersect with chemical problems.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Initial sequencing and analysis of the human genome.
Eric S. Lander;Lauren M. Linton;Bruce Birren;Chad Nusbaum.
The genome of black cottonwood, Populus trichocarpa (Torr. & Gray)
G. A. Tuskan;G. A. Tuskan;S. DiFazio;S. DiFazio;S. Jansson;J. Bohlmann.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal.
The New England Journal of Medicine (2003)
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore;Ghayas C. Issa;Madeleine E. Lemieux;Peter B. Rahl.
Community structure and metabolism through reconstruction of microbial genomes from the environment
Gene W. Tyson;Jarrod Chapman;Jarrod Chapman;Philip Hugenholtz;Eric E. Allen.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: